CLINTON, N.J., April 11, 2011 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients in the hospital and ICU settings, today announced the introduction of its next-generation drug-delivery system, the INOMAX DSIR, in neonatal intensive care units (NICUs) within hospitals throughout the United States. The INOMAX DSIR recently has been launched in Canada and Australia.
The INOMAX DSIR is a proprietary drug-delivery system that delivers the drug, INOMAX® (nitric oxide) for inhalation, the only drug approved by the U.S. Food and Drug Administration (FDA) to treat hypoxic respiratory failure (HRF) associated with pulmonary hypertension in term and near-term infants, which includes infants born at a gestational age of at least 34 weeks. HRF is a serious condition in which blood vessels in the lungs constrict, making it difficult to oxygenate blood. INOMAX relaxes pulmonary blood vessels, improves oxygenation and treats HRF in this delicate newborn population.
Ikaria continually develops new technologies to improve upon its existing drug-delivery systems. The third-generation INOMAX DSIR, which has been in development since 2008, is an advance over the second-generation INOMAX DS and the early-generation INOvent® drug-delivery systems.
The INOMAX DSIR utilizes infrared technology to link the device and cylinder allowing expanded informatics on use of INOMAX therapy. The INOMAX DSIR, like the INOMAX DS, is constructed for ease of use and contains multiple back-up warnings and alarm features to ensure the safe, consistent and reliable delivery and monitoring of INOMAX. With its compact size and weight, the INOMAX DSIR offers improved system management, such as drug usage tracking and various reminders to assist in the proper administration of INOMAX therapy. Like the INOMAX DS, the INOMAX DSIR is compatible wi